2012
Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era.
Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.Peer-Reviewed Original ResearchAdjuvant therapyOncotype DXHormonal therapyPatient ageStage IPractice patternsEarly-stage breast cancerAdjuvant hormonal therapyNational Cancer DatabaseProportion of patientsUse of chemotherapyBreast cancer patientsLog-binomial regressionBr-CANode negativePrevalence ratiosToxic therapiesCancer patientsPredictive biomarkersCancer DatabaseTreatment utilizationBreast cancerChemotherapyPatientsTherapy
2009
Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2.
Misra D, Adelson K, Halpern M, Jaffer S, Nagi C, Bleiweiss I, Mandeli J, Raptis G, Germain D. Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2. Cancer Research 2009, 69: 3035-3035. DOI: 10.1158/0008-5472.sabcs-09-3035.Peer-Reviewed Original ResearchNode-negative breast cancerOncotype DX recurrence scoreOncotype DXRecurrence scoreDX recurrence scoreNegative breast cancerBreast cancerTamoxifen resistanceCyclin D1 overexpressionCyclin D1Cyclin D1 expressionFree survivalOverall survivalEarly-stage node-negative breast cancerColorectal Cancer Study GroupLower relapse-free survivalTamoxifen-resistant breast cancerD1 expressionAdjuvant tamoxifen therapyCancer Study GroupProgression-free survivalUse of chemotherapyResistant breast cancerHigh cyclin D1 expressionHigh recurrence score